Novartis to begin trial with canakinumab in COVID-19 pneumonia patients

Novartis to begin trial with canakinumab in COVID-19 pneumonia patients

Source: 
Pharmaceutical Business Review
snippet: 

Novartis has unveiled plans to begin a phase III clinical study to evaluate canakinumab, an interleukin (IL)-1β blocker, in patients with COVID-19 pneumonia.